Neurocrine Snags $75M to Hunt for Products to License

September 2009
Bioworld Week;9/21/2009, Vol. 17 Issue 38, p1
The article reports on the purchase negotiation made by Neurocrine Biosciences Inc. with Kingsbridge Capital Ltd. in the U.S. It states that Neurocrine will purchase the shares of Kingsbridge through 75 million dollars warrant-free equity financing. According to Neurocrine chief executive officer (CEO) Kevin Gorman, the partnership will fund the committed equity financing facility (CEFF) which will be used to in-license other products.


Related Articles

  • Neurocrine Snares $75M CEFF to Hunt for Products to License. Hollingsworth, Catherine // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p1 

    The article reports on the success of San Diego, California-based pharmaceutical company Neurocrine Biosciences Inc. in securing a commitment from Kingsbridge Capital Ltd. to buy shares in the company. The deal will be done through a warrant-free equity financing in which Neurocrine will be...

  • Neurocrine secures $75 million committed equity financing facility.  // PharmaWatch: CNS;Nov2009, Vol. 8 Issue 11, p13 

    The article reports on the move of Neurocrine Biosciences Inc., a biopharmaceutical company, to enter a committed equity financing facility (CEFF) with private investment group Kingsbridge Capital. Under the said agreement, Kingsbridge has to provide up to 75 million dollars of capital from...

  • Neurocrine Biosciences Has Public Stock Offering.  // San Diego Business Journal;12/18/2000, Vol. 21 Issue 51, p14 

    Reports on shares of common stock issued by Neurocrine Biosciences Inc. in December 2000. Option offered to underwriters to buy additional shares to cover over-allotments; Price of Neurocrine shares on December 7, 2000.

  • WEEK IN REVIEW.  // BioWorld Insight;1/23/2012, Vol. 20 Issue 4, p5 

    The article offers news briefs related to pharmaceuticals in the U.S. including the 20.7-million-dollar raised by Neurocrine Biosciences Inc. in a public stock offering, a 95-million-dollar epigenetics deal signed by Constellation Pharmaceuticals Inc. with Roche AG, and the plans of Takeda...

  • Märklin buyer wants $44 million back.  // Model Retailer;Nov2009, Vol. 35 Issue 11, p10 

    The article reports on the bid of investment group Kingsbridge Capital to recover almost 44 million U.S. dollars from international consulting firm Alix Partners which provided it with restructuring advice when it purchased Märklin in 2006. It is said that this case could set a precedent in...

  • NEUROCRINE BIOSCIENCES. Investor's Business Daily // Investors Business Daily;6/9/2015, pA02 

    The article reports that biopharmaceutical company Neurocrine Biosciences has experienced a stocks decline after suspending two studies on congenital adrenal hyperplasia treatment.

  • Neurocrine moves up on trial. Investor's Business Daily // Investors Business Daily;10/9/2015, pA02 

    The article reports on the increase in shares of biotechnology firm, Neurocrine Biosciences Inc., following an announcement of the success of the late-stage trial of its drug candidate NBI-98854 for tardive dyskinesia.

  • Pfizer: Unlikely To Bid for Neurocrine. Hamerman, Joshua // Mergers & Acquisitions Report;3/27/2006, Vol. 19 Issue 12, p1 

    Focuses on the disagreement of some analysts with the prediction that Pfizer Inc. will acquire Neurocrine Biosciences Inc. Drugs developed by Neurocrine; Projected value of Neurocrine if it is acquired by Pfizer, according to a Sanford C. Bernstein analyst; Factors that make it impossible for...

  • Stratagene Announces Merger With O.C. Firm. Webb, Marion // San Diego Business Journal;8/4/2003, Vol. 24 Issue 31, p9 

    Reports developments in the biotechnology sector in California as of August 2003. Progress of the merger proceeding between Stratagene Inc. and Hycor Biomedical Inc.; Plan of Neurocrine Biosciences Inc. for the testing of its multiple sclerosis treatment; Target schedule for the release of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics